Apr 06, 2018
Valeant Will Release First-Quarter 2018 Financial Results On May 8
Mar 12, 2018
Valeant And One Of Its Subsidiaries Commence Cash Tender Offers For Up To $1,250,000,000 Outstanding Principal Amount
Mar 12, 2018
Valeant Announces Launch Of Private Offering Of Senior Notes
Mar 12, 2018
Valeant Announces Pricing of Private Offering of Senior Notes
Mar 12, 2018
Valeant And One Of Its Subsidiaries Announce Upsize Of Cash Tender Offers To $1,500,000,000 Outstanding Principal Amount
Mar 08, 2018
Valeant To Participate At The 2018 Barclays Global Healthcare Conference
Feb 28, 2018
Valeant Announces Fourth-Quarter And Full-Year 2017 Results And Provides 2018 Guidance
Feb 27, 2018
Valeant Announces Licensing Agreement With Kaken Pharmaceutical Co., Ltd. To Develop And Commercialize New Chemical Entity For Psoriasis
Feb 14, 2018
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For JEMDEL(TM) Plaque Psoriasis Treatment
Feb 09, 2018
Salix Provides Update on FDA Submission for PLENVU®*
Jan 25, 2018
Valeant Will Reduce Debt By An Additional $200 Million
Jan 12, 2018
Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
Jan 09, 2018
Valeant Provides Company Update At The 36th Annual J.P. Morgan Healthcare Conference
Jan 08, 2018
Bausch + Lomb Receives CE Mark From The European Commission For The Stellaris Elite(TM) Vision Enhancement System, Including The Vitesse(TM) Vitrectomy System
Jan 03, 2018
Valeant Pays Down $300 Million Of Senior Secured Term Loans
Jan 03, 2018
Valeant To Present At The 36th Annual J.P. Morgan Healthcare Conference
Dec 29, 2017
Valeant Announces Preliminary Resolution Of Allergan Shareholder Securities Litigation
Dec 22, 2017
Bausch + Lomb Receives FDA Approval of LUMIFY(TM) - The Only Over-The-Counter Eye Drop With Low-Dose Brimonidine For The Treatment Of Eye Redness
Dec 20, 2017
Valeant Completes Sale Of Sprout Pharmaceuticals Subsidiary To Former Shareholders Of Sprout Pharmaceuticals
Dec 18, 2017
Bausch + Lomb Begins Distribution Of VYZULTA(TM) (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers